Brokerages Set Alumis Inc. (NASDAQ:ALMS) Price Target at $26.57

Shares of Alumis Inc. (NASDAQ:ALMS) have earned a consensus rating of “Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $26.57.

ALMS has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Robert W. Baird started coverage on Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target for the company. Baird R W upgraded Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. HC Wainwright cut their price objective on Alumis from $26.00 to $19.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Oppenheimer started coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company.

Alumis Stock Performance

ALMS stock opened at $4.85 on Wednesday. Alumis has a 52-week low of $4.74 and a 52-week high of $13.53. The stock’s 50 day moving average is $7.05 and its two-hundred day moving average is $9.62.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALMS. Foresite Capital Management VI LLC acquired a new position in Alumis during the fourth quarter valued at $33,033,000. Samsara BioCapital LLC acquired a new position in Alumis during the third quarter valued at $34,886,000. Geode Capital Management LLC acquired a new position in Alumis during the third quarter valued at $3,266,000. Norges Bank acquired a new position in Alumis during the fourth quarter valued at $1,606,000. Finally, Foresite Capital Management V LLC raised its position in Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after buying an additional 194,459 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.